The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

Abstract

PurposeTo compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year.Materials and MethodsWe retrospectively investigated patients who suffered from BPH for 1 year between January 2005 and December 2008. For treatment groups, we divided the patients into two groups: one was treated with alfuzosin and finasteride and the other was treated with alfuzosin and dutasteride. At the beginning of treatment, the patients underwent transrectal ultrasonography and measurement of urine flow rate, residual urine volume, PSA, and International Prostate Symptom Score (IPSS). Patients with diseases affecting urinary function were excluded. We not only analyzed the data at the time of initial treatment, but also after 1 year of treatment. A total of 219 patients were able to be evaluated for 1 year.ResultsBoth finasteride and dutasteride reduced PSA and prostate volume significantly. The comparison between groups showed a more significant reduction of PSA (p=0.020) and prostate volume (p=0.052) in the dutasteride group. Other parameters did not differ significantly between the groups.Conclusions5-α Reductase inhibitors for BPH treatment reduced PSA and prostate volume significantly when the patients were treated for 1 year. Administration of dutasteride is considered to be more effective in reducing PSA and prostate volume. Therefore, dutasteride should not be considered equivalent to finasteride in the reduction rate of PSA. The intensity of dutasteride must be reevaluated in comparison with finasteride.

Review and update of benign prostatic hyperplasia in general practice

“…1 Men should be warned that 5-ARI therapy can decrease PSA levels by approximately 50% after 6-12 months of treatment. 16,17 As a result, in men on a 5-ARI, an increase in PSA above the nadir should prompt closer evaluation of PSA levels to exclude an upward trend suggestive of prostate cancer, rather than waiting for the PSA to be elevated outside the reference range before considering urological evaluation.…”

Management Approaches to Congenital Adrenal Hyperplasia in Adolescents and Adults; Latest Therapeutic Developments

“…Recently, inhibitors of 5 -reductase, finasteride and dutasteride, have been utilized to reduce the conversion of testosterone to dihydrotestosterone, the steroid compound most directly responsible for acne, alopecia, and hirsutism. Of the two medications, dutasteride is the more effective because it inhibits both forms of the enzyme (Choi et al, 2010). Additional strategies include the use of electrolysis for permanent removal of unwanted hair, laser for semi-permanent hair removal, depilatories for temporary hair removal, cosmetic bleaching of hair, benzoyl peroxide and retinoic acid derivatives for acne control and tetracyline, and its derivatives for suppression of Propionibacterium acnes in acne.…”

Spontaneous Progressive Diminution of Prostate-Specific Antigen Levels as a Clue to Secondary Hypogonadism and Ultimately a Pituitary Macroadenoma

“…Male hormone replacement therapy may also raise PSA levels, but this is controversial (3,4). PSA reductions may occur with surgery, radiation, or anti-androgen therapy (5)(6)(7). Spontaneous lowering of PSA levels is unusual and may predict testosterone deficiency (8).…”